Boehringer Ingelheim Venture Fund
Corporate VCIngelheim am Rhein · Seed–Growth · 7 people tracked
Investment thesis
Boehringer Ingelheim Venture Fund, established in 2010, invests in biotechnology companies developing therapeutics in immuno-oncology, regenerative medicine, and gene therapy, including platform technologies and novel vaccines. The fund targets early-stage companies addressing unmet medical needs through translational research and scientific innovation.
Source: firm website, verified Jul 31, 2026.
Team · 7 people
from curated
What they invest in
from 11 of 11 portfolio companiesBiotech ×11Healthtech ×9Deep Tech ×6Medical Devices ×6AI & Machine Learning ×4Digital Health ×4
HQs:Germany×3Belgium×2United States×2France×1Sweden×1Singapore×1
Investments · 11 tracked
founders shown can be your intro pathAcousia Therapeutics develops small-molecule drug candidates with a dual mode of action for treating acute and chronic sensorineural hearing loss (SNHL), targeting outer hair cells in the inner ear to preserve and enhance natural hearing.
BiotechDigital HealthHealthtechMedical DevicesTübingen, DE
Hubert Löwenheim(Founder / Board Member)
Co-investorsKfWCreathor VenturesLBBW Venture Capital GmbHEsperante Ventures
ArrePath is a biotechnology company that applies AI/ML to drug discovery and development.
AI & Machine LearningBiotechDeep Tech
Zemer Gitai(Founder and SAB Chair)Kevin Krause(President and Chief Executive Officer)
Co-investorsInnospark VenturesInsight Partners
DiogenX is a preclinical-stage biotech company developing biologic therapeutics aimed at restoring insulin-producing beta cells for people with Type 1 diabetes.
BiotechDeep TechDigital HealthHealthtechMarseille, FR
Benjamin Charles(Co-Founder & CEO)Patrick Collombat(Co-Founder & Scientific Advisor)inJean-Pascal Tranié(Co-Founder)in
Co-investorsAdBio partnersRoche Venture FundSunstone CapitalJDRF T1D Fund
Nuevocor is a biotechnology company developing gene therapy treatments for cardiovascular and metabolic diseases.
BiotechDigital HealthHealthtechMedical DevicesSingapore, SG
Brian Burke(Co-Founder and Advisor)Mark Kay(Co-Founder and Advisor)Colin Stewart(Co-Founder and Advisor)Yann Chong Tan(Co-Founder and Advisor)Monica Shah(Chief Medical Officer)Al Gianchetti(Chief Executive Officer)
Co-investorsAngelini VenturesKurma PartnersClavystBioHighlight CapitalSEEDS Capital
Obulytix develops Precision Lysin Therapeutics, a novel class of engineered biologics designed to target multidrug-resistant Gram-negative bacteria for severe bloodstream and lung infections.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesGhent, BE
Yves Briers(Scientific Founder)in
Co-investorsQbic Fund
Rewind Therapeutics is a biotech company developing first-in-class remyelination therapeutics that aim to repair the myelin sheath in patients with diseases such as multiple sclerosis, optic neuritis, and nerve injuries.
BiotechDeep TechHealthtechLeuven, BE
Co-investorsPMVM VenturesSunstone Capital
Tacalyx develops novel anticancer therapeutics that target Tumor-Associated Carbohydrate Antigens (TACAs), including antibody-drug conjugate programs.
BiotechDeep TechMedical DevicesBerlin, DE
Peter Seeberger(Co-founder (Prof. Dr.))Oren Moscovitz(CSO & Co-founder)
Co-investorsCreathor VenturesKurma PartnerscoparionThuja Capital
Topas Therapeutics develops nanoparticle-based therapies to induce immune tolerance for autoimmune and immune-mediated diseases.
BiotechHealthtech
Hugo Fry(Chief Executive Officer)Christian Schröter(Chief Operating Officer)Cristina de Min(Chief Medical Officer)Anne Burger(Chief Financial Officer)Alex Marshall(Chief Business Officer)
Co-investorsEMBL VenturesGimvBioMedPartnersEpidarex Capital
Asgard Therapeutics develops direct cell reprogramming technologies that convert cancer cells into dendritic cells to restore anti-cancer immune responses.
AI & Machine LearningBiotechHealthtechMedical DevicesLund, SE
Cristiana Pires(Co-founder and CEO)Fábio Rosa(Co-founder and VP of Research)Filipe Pereira(Co-founder and Head of Innovation)
Co-investorsIndustrifondenLU InnovationNovo Holdings
Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy.
BiotechDigital HealthHealthtechMedical DevicesNew York, US
David B. Klein(Founder and CEO)inDavid Klein(Executive Officer, Director)inRandall Stanicky(Executive Officer)in
BoardAlex Zisson(Director)Lee Shapiro(Director)inCris De Luca(Director)in
Co-investorsAccelmed PartnersH.I.G. CapitalH.I.G. HealthBridge PartnersHealth Catalyst CapitalHikma VenturesSanofi Ventures+2 more
Rgenta develops orally available small molecule therapies that target RNA to address diseases previously considered undruggable, with programs in oncology (targeting proteins such as MYB in solid tumors and hematologic cancers) and central nervous system repeat expansion disorders like Huntington's disease.
AI & Machine LearningBiotechDeep TechHealthtechCambridge, US
Travis Wager(Co-founder, President and CSO)Hualin Simon Xi(Executive Officer, Director)Zhiping Weng(Co-founder)Simon Xi(Co-founder and CEO)Jackie Walling(CMO)Debasish Roychowdhury(Director)
Co-investorsDelos CapitalVivo CapitalAMR Action FundKorea Investment PartnersLilly Asia VenturesMatrix Partners China
Portfolio news
latest coverage across their companiesClick Therapeutics · mobihealthnews.com · Apr 17, 2026
Nuevocor · precisionmedicineonline.com · May 9, 2025
Frequently asked questions
- What stage does Boehringer Ingelheim Venture Fund invest at?
- Boehringer Ingelheim Venture Fund invests at the Seed, Series A, Series B, Series C, Growth stages.
- What is Boehringer Ingelheim Venture Fund's typical check size?
- Boehringer Ingelheim Venture Fund typically writes checks of $16.2M.
- What sectors does Boehringer Ingelheim Venture Fund focus on?
- Boehringer Ingelheim Venture Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Boehringer Ingelheim Venture Fund located?
- Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, DE.
Co-investors · 7
Insight Partners is an investment firm focused on accelerating revenue and profit growth in software companies, providing capital and operational support through its Insight Onsite team.
Innospark Ventures is an early-stage investor backing technical founders building AI-driven solutions across healthcare, life sciences, and enterprise.
The JDRF T1D Fund is a venture philanthropy investor focused on type 1 diabetes (T1D), backing companies developing disease-modifying therapies and cures for the condition.
Lilly Asia Ventures (LAV) is a biomedical venture capital firm with offices in Hong Kong, Shanghai, and Palo Alto, backing entrepreneurs building companies focused on breakthrough products that treat disease and improve human health.
Playground Global is a venture capital firm that invests in deep tech companies built by scientists and engineers, spanning next-generation compute, automation, energy, and computational biology.
Distributed Ventures is an early-stage venture firm that leads Seed and Series A investments in companies innovating across the health, insurance, and wealth risk ecosystems.
Canada's leading digital health venture capital firm investing in early-stage and high-growth technology companies transforming healthcare delivery across North America. The firm provides capital alongside hands-on operational guidance, commercial introductions, and go-to-market strategy support.
Firms observed investing alongside Boehringer Ingelheim Venture Fund, from public investor directories. Shared companies are the overlap with Boehringer Ingelheim Venture Fund's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
Capricorn Partners is a Belgium-based, partner-owned independent management company for alternative investment funds, investing in innovative companies across digital, health and clean technologies with an ESG focus.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.